Your browser doesn't support javascript.
loading
TM9SF4 expression in tumor tissues: a novel diagnostic biomarker for gastrointestinal tumors.
Guazzi, Paolo; Zocco, Davide; Isajevs, Sergejs; Zarovni, Natasa; Bianciardi, Laura; Toots, Mart; Sivins, Armands; Leja, Marcis; Chiesi, Antonio; Lozupone, Francesco.
Afiliación
  • Guazzi P; HansaBioMed Life Sciences LTD, Tallinn, Estonia.
  • Zocco D; Exosomics SpA, Siena, Italy.
  • Isajevs S; Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia.
  • Zarovni N; Riga East University Hospital, Riga, Latvia.
  • Bianciardi L; Academic Histology Laboratory, Riga, Latvia.
  • Toots M; Exosomics SpA, Siena, Italy.
  • Sivins A; Exosomics SpA, Siena, Italy.
  • Leja M; HansaBioMed Life Sciences LTD, Tallinn, Estonia.
  • Chiesi A; Institute of Clinical and Preventive Medicine, University of Latvia, Riga, Latvia.
  • Lozupone F; Riga East University Hospital, Riga, Latvia.
Transl Cancer Res ; 9(11): 6652-6659, 2020 Nov.
Article en En | MEDLINE | ID: mdl-35117275
ABSTRACT

BACKGROUND:

The identification of novel biomarkers for the early detection and monitoring of gastric (GC) and colorectal cancer (CRC) is of paramount importance. TM9SF4 is a newly described V-ATPase interacting protein involved in the malignant progression of cancer cells. While TM9SF4 expression pattern and cellular localization have been described in in vitro in tumor cell lines of different histotypes, its expression in gastrointestinal tumor tissues has never been investigated.

METHODS:

In this study, we detected by immunohistochemistry (IHC) in tumor and surrounding healthy tissues TM9SF4, in comparison with clinically adopted biomarkers CEA and CA 19-9 to evaluate TM9SF4 potential as a novel tissue marker for early detection and monitoring of GC and CRC cancers.

RESULTS:

The expression of TM9SF4, CEA and CA 19-9 was evaluated in samples from 108 cancer patients (68 with GC and 40 CRC) and in healthy tissues from 20 non-cancer patients. Our results clearly suggest that TM9SF4 expression was significantly increased in GC and CRC samples and significantly correlated to disease stage in both cancer types.

CONCLUSIONS:

We propose TM9SF4 as highly specific cancer biomarker, exploitable for disease detection and staging of gastrointestinal cancers patients, with tumor tissue levels of expression outperforming those of clinically adopted markers such as CEA and CA 19-9.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: Transl Cancer Res Año: 2020 Tipo del documento: Article País de afiliación: Estonia

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: Transl Cancer Res Año: 2020 Tipo del documento: Article País de afiliación: Estonia